https://www.optimumcomms.com/wp-content/uploads/2024/04/Template_Logo_300x180px-80x80Web_Logos-7.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-11 08:33:262026-03-11 08:33:26Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic
https://www.optimumcomms.com/wp-content/uploads/2024/04/Template_Logo_300x180px-80x80Web_Logos-7.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-11 08:33:262026-03-11 08:33:26Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-10 10:54:112026-03-10 10:54:11Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026
https://www.optimumcomms.com/wp-content/uploads/2026/01/Kainova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-10 08:30:262026-03-10 08:30:26Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
https://www.optimumcomms.com/wp-content/uploads/2026/01/Numares_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-09 17:32:442026-03-09 17:32:44New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-09 11:01:502026-03-09 11:04:44Hansa Biopharma participating at LSX Investival Showcase USA
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-06 17:04:402026-03-06 17:08:55Hansa Biopharma participating at Leerink Global Healthcare Conference
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-05 08:43:252026-03-05 08:43:40PDUFA Action Date for Hansa Biopharma’s Imlifidase BLA Set for December 19, 2026
https://www.optimumcomms.com/wp-content/uploads/2026/02/Synklino-logo-website.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-26 12:04:472026-02-26 12:04:47Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-26 09:08:472026-02-26 09:08:47Oncoinvent ASA: Second half 2025 results
https://www.optimumcomms.com/wp-content/uploads/2026/02/Link-Biologics_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-24 08:51:582026-02-24 08:52:25Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-23 17:06:092026-02-23 17:06:09Hansa Biopharma presenting at TD Cowen’s 46th Annual Health Care Conference
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-20 09:39:312026-02-20 09:39:52Biocomposites to launch SYNICEM bone cement in UK to ease supply crisis
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-20 08:30:482026-02-20 10:05:48Philanthropic Partnership Backs Country-Led Research to Guide the Use of AI in Health
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-19 08:49:162026-02-19 08:49:16Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA
https://www.optimumcomms.com/wp-content/uploads/2026/02/Lario_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-19 08:31:492026-02-19 08:31:49Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
https://www.optimumcomms.com/wp-content/uploads/2026/02/Pharmaacelera_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-18 08:37:162026-02-18 08:37:16Pharmacelera raises €6M to expand in U.S. and build out its high speed, high accuracy, deep tech drug discovery platformWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
